Canada’s Drug Agency Revised Its Reimbursement Review Procedures From August 2026

Canada’s Drug Agency reviews drugs for public reimbursement and issues recommendations to the federal, provincial and territorial public drug plans that take part in its processes. On 29 January 2026 the agency published a document titled Improvements to the Drug Reimbursement Review Process, which proposed changes to how reconsiderations and resubmissions are handled and introduced a streamlined review option.

The consultation proposed treating reconsideration requests as new projects with standard timelines, and set out proposed review timelines of 180 days for standard reviews, 150 days for streamlined reviews and 120 days for reconsiderations. In a joint submission dated 26 February 2026, Innovative Medicines Canada and BIOTECanada expressed concern that the reconsideration changes could delay review and reimbursement for many therapies and reduce opportunities for patient and clinician comment.

The agency published the updated Procedures for Reimbursement Reviews on 30 April 2026. According to the agency’s newsletter and law firm summaries, new analyses or studies must now be addressed through a resubmission rather than a reconsideration. The enhanced reconsideration process discloses the sponsor’s reason for requesting reconsideration and publishes the review reports presented to the expert committee.

The procedures set explicit criteria distinguishing standard resubmissions, with a 180-day timeline, from streamlined resubmissions, with a 150-day timeline. Reported criteria for a streamlined resubmission include that the sponsor provides only one new source of clinical information, alongside other conditions. After the consultation, the agency decided to keep the 10-business-day period for patient and clinician groups to comment on draft recommendations, and not to introduce the separate reconsideration-specific input period it had proposed.

The scope of testing procedure assessments is extended to cover complementary tests as well as companion diagnostics. Eligibility depends on updated scope and relevance criteria, with relevance focused on new health system impacts.

The publication of the sponsor’s reason for reconsideration and of the review reports presented to the expert committee increases the transparency of the reconsideration stage. Patient and clinician groups, public drug plans and other sponsors will be able to see the basis on which a sponsor has challenged a draft recommendation, which may influence how sponsors frame their requests.

The updated procedures apply to submissions filed from August 2026 and to expert committee meetings from January 2027. Submissions already under review before that point should be checked against the transition provisions in the agency’s published procedures. The detailed criteria in this brief are drawn from the agency’s newsletter and from law firm summaries; the full procedures document should be consulted for exact wording.

The agency also reported new data on health technology assessment timelines alongside the procedures. Separately, it has consulted on an expanded rolling review pilot, under which drug applications filed before a Health Canada regulatory decision may be eligible for rolling review; the date and final form of that pilot could not be confirmed at the time of checking.

Sponsors facing a negative or restricted draft recommendation now need to decide early whether their response depends on new evidence. If it does, a resubmission is the appropriate route, and the choice between a standard and a streamlined resubmission will depend on the number and type of new clinical sources. Reconsideration is reserved for issues that can be addressed with the evidence already reviewed.

Sponsors of drugs that rely on a diagnostic or complementary test should plan for a testing procedure assessment where the test meets the updated criteria. Pubrica’s summary is for information and does not replace the agency’s procedures or advice from the agency.

Sponsors should also build the revised timelines into launch and listing plans. A streamlined resubmission at 150 days and a standard resubmission at 180 days, together with the separate reconsideration route, affect how quickly a revised recommendation can be obtained after a negative or restricted outcome. Planning evidence generation so that a single additional clinical source can address the main uncertainty may allow use of the shorter streamlined route.